# Phase 1 Scleroderma, Systemic trials recruiting: 31 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 31 trials in phase 1 for Scleroderma, Systemic that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Scleroderma, Systemic trials: 31 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/scleroderma-systemic

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 31
- Recruiting or not yet: 31
- Read on: November 19, 2026

## Trials

The 25 newest of 31, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 30, 2026 | NCT07906145 | A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases | Shanghai Qilu Pharmaceutical Research and Development Center LTD | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus, Rheumatoid Arthritis (RA), Primary Sjögren's Syndrome (pSS), Systemic Sclerosis (SSc) | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906145) |
| October 14, 2026 | NCT07873931 | A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases | Bristol-Myers Squibb | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies, Systemic... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873931) |
| October 2, 2026 | NCT07854483 | C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory... | AbelZeta Inc. | Phase 1 | Not yet recruiting | Systemic Sclerosis (SSc), Systemic Sclerosis, Systemic Sclerosis (Scleroderma), Systemic Sclerosis - 2013 ACR/EULAR... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07854483) |
| July 28, 2026 | NCT07732309 | A Study of ATG-201 in Adult Participants With Autoimmune Diseases | Antengene Biologics Limited | Phase 1 | Recruiting | Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Sjogren's Disease, Autoimmune Diseases | 149 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07732309) |
| July 28, 2026 | NCT07729995 | BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease | Luminary Therapeutics | Phase 1 | Not yet recruiting | Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE), Dermatomyositis (DM), Systemic Sclerosis (SSc) | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07729995) |
| June 30, 2026 | NCT07676266 | A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy | The Affiliated Hospital of Qingdao University | Phase 1 | Not yet recruiting | Multiple Sclerosis (MS), Myasthenia Gravis (MG), Neuromyelitis Optica Spectrum Disorder, Systemic Lupus Erythematosus... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07676266) |
| June 16, 2026 | NCT07649265 | A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 | Recruiting | Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Sjögren's Disease | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07649265) |
| April 22, 2026 | NCT07544225 | Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic... | Gustave Roussy, Cancer Campus, Grand Paris | Phase 1 | Not yet recruiting | Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Sjogren's Disease With Dry Eyes, Systemic Sclerosis... | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07544225) |
| April 13, 2026 | NCT07523282 | Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases | Shenzhen MagicRNA Biotechnology Co., Ltd | Phase 1 | Not yet recruiting | Autoimmune Disease, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc) | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523282) |
| February 17, 2026 | NCT07413341 | A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases | Therorna | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome (SS), Systemic Sclerosis (SSc), Inflammatory Myopathy, ANCA... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07413341) |
| December 26, 2025 | NCT07305116 | CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease | The Children's Hospital of Zhejiang University School of Medicine | Phase 1 | Recruiting | Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy... | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07305116) |
| December 16, 2025 | NCT07284797 | A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases | Xencor, Inc. | Phase 1 | Recruiting | Healthy, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Sjögren's Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284797) |
| November 19, 2025 | NCT07236801 | Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases | China Immunotech (Beijing) Biotechnology Co., Ltd. | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE), Systemic Sclerosis, Sjogren's Syndrome (SS), Inflammatory Myopathy, Anti-Neutrophil... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07236801) |
| September 19, 2025 | NCT07184450 | Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis, Systemic Sclerosis (SSc), Primary... | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07184450) |
| September 11, 2025 | NCT07167537 | A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases | Beijing GoBroad Hospital | Phase 1 | Recruiting | Systemic Sclerosis (SSc), Primary Sjogren&#39;s Syndrome | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07167537) |
| August 11, 2025 | NCT07115745 | A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Phase 1 | Recruiting | Refractory Autoimmune Diseases | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07115745) |
| August 5, 2025 | NCT07104721 | A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases | China Immunotech (Beijing) Biotechnology Co., Ltd. | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Systemic Sclerosis (SSc), Inflammatory Myopathy... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07104721) |
| July 25, 2025 | NCT07085676 | Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases | Sponsor not shown (see the record) | Phase 1 | Recruiting | Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM), Rheumatoid Arthritis (RA), Systemic Lupus... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07085676) |
| July 25, 2025 | NCT07085104 | A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease | Allogene Therapeutics | Phase 1 | Recruiting | Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07085104) |
| May 20, 2025 | NCT06980597 | A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases | Beijing GoBroad Hospital | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), ANCA Associated... | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06980597) |
| May 18, 2025 | NCT06978738 | UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases | Changzhou No.2 People's Hospital | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia, Myasthenia Gravis, Systemic Sclerosis, ANCA-Associated... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06978738) |
| May 18, 2025 | NCT06978647 | A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases | China Immunotech (Beijing) Biotechnology Co., Ltd. | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Inflammatory Myopathy, Anti-Neutrophil Cytoplasmic... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06978647) |
| April 23, 2025 | NCT06941129 | CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | Recruiting | Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Inflammatory Myopathy, ANCA-Associated Vasculitis (AAV)... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06941129) |
| April 13, 2025 | NCT06925542 | A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease | CRISPR Therapeutics | Phase 1 | Recruiting | SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis, Inflammatory Myopathy... | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06925542) |
| February 12, 2025 | NCT06822881 | CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive... | Beijing GoBroad Hospital | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06822881) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| China Immunotech (Beijing) Biotechnology Co., Ltd. | 3 |
| Beijing GoBroad Hospital | 3 |
| Antengene Biologics Limited | 1 |
| [Chongqing Precision Biotech Co., Ltd](https://specstream.ai/data/clinical-trials/company/chongqing-precision-biotech-co-ltd) | 1 |
| [Miltenyi Biomedicine GmbH](https://specstream.ai/data/clinical-trials/company/miltenyi-biomedicine-gmbh) | 1 |
| Changzhou No.2 People's Hospital | 1 |
| Jiangsu Renocell Biotech Company | 1 |
| Shanghai Qilu Pharmaceutical Research and Development Center LTD | 1 |
| Gustave Roussy, Cancer Campus, Grand Paris | 1 |
| AbelZeta Inc. | 1 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| Shenzhen MagicRNA Biotechnology Co., Ltd | 1 |
| National Cancer Institute (NCI) | 1 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 1 |
| Luminary Therapeutics | 1 |
| Therorna | 1 |
| RenJi Hospital | 1 |
| The Children's Hospital of Zhejiang University School of Medicine | 1 |
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 1 |
| The Affiliated Hospital of Qingdao University | 1 |
| [Otsuka Pharmaceutical Development & Commercialization, Inc.](https://specstream.ai/data/clinical-trials/company/otsuka-pharmaceutical-development-and-commercialization-inc) | 1 |
| [Xencor, Inc.](https://specstream.ai/data/clinical-trials/company/xencor-inc) | 1 |
| Allogene Therapeutics | 1 |
| [Fate Therapeutics](https://specstream.ai/data/clinical-trials/company/fate-therapeutics) | 1 |
| CRISPR Therapeutics | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 16 |
| United States | 9 |
| France | 4 |
| Germany | 3 |
| Australia | 3 |
| Israel | 2 |
| Canada | 2 |
| Poland | 2 |
| Spain | 2 |
| Belgium | 1 |
| Netherlands | 1 |
| Brazil | 1 |
| Czechia | 1 |
| Romania | 1 |
| Sweden | 1 |
| United Kingdom | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Rehabilitation centers in the United States](https://specstream.ai/data/businesses/rehabilitation-centers/united-states)
- [Vehicle parts manufacturers in the United States](https://specstream.ai/data/businesses/vehicle-parts-manufacturers/united-states)
- [Banks in the United States](https://specstream.ai/data/businesses/banks/united-states)
- [Diagnostic imaging centers in the United States](https://specstream.ai/data/businesses/diagnostic-imaging-centers/united-states)
- [Handyman services in the United States](https://specstream.ai/data/businesses/handyman-services/united-states)
- [Mediterranean restaurants in the United States](https://specstream.ai/data/businesses/mediterranean-restaurants/united-states)
